International Stem Cell Corporation Strengthens Intellectual Property Portfolio

International Stem Cell Corporation Strengthens Intellectual Property Portfolio 
CARLSBAD, CA -- (Marketwire) -- 02/15/13 --  International Stem Cell
Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or
"the Company"), a California-based biotechnology company, today
announced amendments to the license agreements with Advanced Cell
Technology, Inc.  
The license agreements, first entered into in 2004 and amended in
2005, granted ISCO access to a range of ACT's patents and patent
applications for the use of various technologies in a limited set of
human tissues.  
The amendments extend ISCO's existing rights in the area of
parthenogenesis, and the therapeutic use of parthenogenetically
derived stem cells for treating any human diseases. Pursuant to the
amended agreements ISCO now has an exclusive world-wide license to
ACT's patents and applications covering the uses of
parthenogenetically derived stem cells in generating human tissue.  
"We're excited to have extended our portfolio of intellectual
property which not only allows us to develop new therapeutic and
business opportunities, but also makes the possibility of partnering
with big pharma practical," commented Dr. Andrey Semechkin, CEO and
Co-Chairman of ISCO. 
About International Stem Cell Corporation
 International Stem Cell
Corporation is focused on the therapeutic applications of human
parthenogenetic stem cells (hpSCs) and the development and
commercialization of cell-based research and cosmetic products.
ISCO's core technology, parthenogenesis, results in the creation of
pluripotent human stem cells from unfertilized oocytes (eggs) hence
avoiding ethical issues associated with the use or destruction of
viable human embryos. ISCO scientists have created the first
parthenogenetic, homozygous stem cell line that can be a source of
therapeutic cells for hundreds of millions of individuals of
differing genders, ages and racial background with minimal immune
rejection after transplantation. hpSCs offer the potential to create
the first true stem cell bank, UniStemCell. ISCO also produces and
markets specialized cells and growth media for therapeutic research
worldwide through its subsidiary Lifeline Cell Technology
(www.lifelinecelltech.com), and stem cell-based skin care products
throug
h its subsidiary Lifeline Skin Care (www.lifelineskincare.com).
More information is available at www.internationalstemcell.com.  
To receive ongoing corporate communications via email, visit:
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 
To like our Facebook page or follow us on Twitter for company updates
and industry related news, visit:
www.facebook.com/InternationalStemCellCorporation and
www.twitter.com/intlstemcell 
Safe harbor statement 
 Statements pertaining to anticipated
developments, the potential use of technologies to develop
therapeutic products, potential strategic partnerships and other
opportunities for the company and its subsidiaries, along with other
statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including,
but not limited to statements that contain words such as "will,"
"believes," "plans," "anticipates," "expects" or "estimates") should
also be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or
commercialization of potential products and the management of
collaborations, regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing
uses, and maintenance of intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the company's business,
particularly those mentioned in the cautionary statements found in
the company's Securities and Exchange Commission filings. The company
disclaims any intent or obligation to update forward-looking
statements.  
Contacts:
International Stem Cell Corporation
Dr. Simon Craw
Executive Vice President
Phone: 760-940-6383
Email: ir@intlstemcell.com  
Investor Relations:
MZ Group
Mark McPartland
Senior Vice President
Phone: 212-301-7130
Email: markmcp@mzgroup.us
Web: www.mzgroup.com